Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units. Other offerings include a newborn genetic analysis panel, a front-line test to sequence ataxia-related variants, and patient-initiated genetic testing via Picture Genetics. They also provide comprehensive whole exome, clinical exome, whole genome, mutation, and repeat expansion testing, alongside research service tests. For COVID-19, the company delivers next-generation sequencing, reverse transcription polymerase chain reaction (RT-PCR), and antigen-based diagnostic solutions for SARS-CoV-2. Beyond genetic and COVID-19 diagnostics, Fulgent Genetics performs advanced laboratory analyses such as flow cytometry for cell analysis and malignancy monitoring, fluorescence in-situ hybridization (FISH) for specific DNA sequence detection, immunohistochemistry (IHC) to visualize cellular antigens, and cytogenetics for assessing chromosomal anomalies, in addition to molecular testing for both hematopoietic and solid tumors. Their clientele is broad, including insurance companies, hospitals, medical institutions, fellow laboratories, government agencies, payors, municipal bodies, major corporations, and direct patients. The company has formed a strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. Founded in 2011 and headquartered in Temple City, California, the company was previously known as Fulgent Diagnostics, Inc. before adopting its current name in August 2016.
Subscribe to see Fulgent Genetics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Fulgent Genetics, Inc. is a healthtech company headquartered in El Monte, United States. It is publicly listed (FLGT) with a market capitalisation of $718M. Xcout tracks 14 named people at Fulgent Genetics, Inc., including Ming Hsieh (Chairman & Chief Executive Officer).
As of 16 November 2026. Source: Xcout Intel.
8 more named people on record for Fulgent Genetics, Inc., with roles, board committees and tenure — see the full roster →
142 institutions reported a position for the quarter ending 30 June 2026, and 6 insiders hold at least 0.1% of the shares.
| Holder | % of shares outstanding |
|---|---|
| BlackRock | 8.30% |
| Vanguard | 4.00% |
| Ming Hsieh | 4.00% |
| Acadian Asset Management | 3.70% |
| Hanlin Gao | 3.60% |
| Other institutions | 41.00% |
| Other insiders | 2.90% |
| Not held by 13F institutions or listed insiders | 32.50% |
The full list of 142 institutions, with share counts and what each bought or sold since the previous quarter.
Sign in to see it, or subscribe →
Source: SEC Form 13F filings, period ending 30 June 2026; shares outstanding from the company's 10-Q as of 27 July 2026. 13F covers the US-listed holdings of investment managers with more than $100 million under management and is filed up to 45 days after the quarter ends. A firm that files under several names (Vanguard files as two managers) is one row, with its filers listed under it. Individuals are company insiders (directors, officers and 10% owners) holding at least 0.1% of the shares, from their latest SEC Form 3, 4 or 5 (newest 3 September 2026), counting shares held directly and through trusts and other entities they report, including high-vote class shares (such as Class B); options and restricted stock units are not counted. They are a separate slice from the 13F institutions, so the ring adds up to 100%: what is left is held by smaller insiders, retail investors and anyone else who does not file.
A few of Fulgent Genetics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Valius Health, Inc. provides comprehensive cancer diagnostic and tumor profiling services for patients and oncologists. The company analyzes tumor DNA, RNA, and proteins to identify actionable therapeutic targets and treatment options.
LineaGen, Inc. is a genetic testing and research company that provides advanced neurodevelopmental diagnostic evaluations. The company has conducted large-scale studies focused on genetic variants and operates as a part of Bionano Laboratories.
Probably Genetic is a healthcare technology company focused on helping identify rare genetic diseases through genetic testing and clinical software. It serves patients with undiagnosed conditions and the healthcare professionals involved in their diagnosis and care.
Lab Angelus, Inc. builds digital infrastructure and coordination platforms that connect community pathology laboratories with molecular reference laboratories for precision oncology. Its flagship product, LabDispatch, streamlines cancer specimen logistics and testing workflows to help patients receive timely molecular profiling and targeted treatments.
Rightangled is a UK healthtech company that provides genetic and pharmacogenomic testing to help identify how individuals may respond to medicines. It serves patients and healthcare professionals seeking more personalized treatment and medication decisions.
24Genetics is a Spain-based genetic testing company that analyzes DNA samples, typically collected with a saliva kit, to provide reports on areas such as ancestry, health predispositions, nutrition, pharmacogenetics, skin, and sports genetics. It serves individual consumers as well as organizations and healthcare-related professionals seeking personal genetic information and testing services.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Fulgent Genetics, Inc.? Suggest a correction · Work at Fulgent Genetics, Inc.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.